louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00871598: BTT1023 in Psoriasis
Official title: A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Plaque Psoriasis - a Double-blind Randomized Placebo-controlled Sequential Group Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Plaque Psoriasis
Keywords: plaque psoriasis
BTT1023
safety
pharmacokinetics
Lead sponsor: Biotie Therapies Corp.
Sponsor class: INDUSTRY
First posted: 2009-03-30
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with plaque psoriasis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.


Eligibility criteria: Inclusion Criteria:

* Plaque psoriasis affecting at least 8% of the body surface area and scoring 8 or higher in the psoriasis area and severity index

Exclusion Criteria:

* Seropositive for infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus; Tuberculosis; Acute systemic infection;
* Treatment with a monoclonal antibody therapy within 12 weeks prior to study entry;
* An absolute indication for a known effective treatment

Primary outcomes:
measure: Adverse events
timeFrame: 12 weeks
measure: Plasma concentrations of BTT1023
timeFrame: 12 weeks
Secondary outcomes:
measure: Change in Psoriasis Area and Severity Index (PASI)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Biotie investigational site
city: Berlin
country: Germany
facility: Biotie investigational site
city: Dresden
country: Germany
facility: Biotie investigational site
city: Görlitz
country: Germany
facility: Biotie Investigational Site
city: Leipzig
country: Germany
facility: Biotie investigational site
Study officials:
References:
Clinical trial NCT03045445: "Double Low-Dose" DECT for HCC Imaging
Official title: Comparison of Image Quality Between "Double Low-Dose" Dual Energy Liver CT and Standard Contrast Enhanced Liver CT in Patients at High-risk of HCC: Prospective, Randomized Single Center Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HCC
Keywords: CT
dual energy
low dose
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Philips Healthcare
First posted: 2017-02-07
Enrollment: 68
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Hypothesis: double low-dose protocol provide better lesion conspicuity than standard protocol CT in patients at high-risk of HCC.

patients who are scheduled for CECT for HCC diagnosis or surveillance are eligible for this study and allocated to either standard protocol or double-low dose protocol using spectral CT with low radiation dose and low dose of contrast media, within clinically accpetable range.


Eligibility criteria: Inclusion Criteria:

* high risk of HCC (chronic hepatitis B or C, or LC of any cause)
* signed informed consent
* scheduled for contrast enhanced liver CT for HCC surveillance or diagnosis

Exclusion Criteria:

* no risk factor for HCC
* history of iodine hypersensitivity
* renal dysfunction (Estimated GFR \< 30mL/min/1.73m2) or on dialysis
* metformin medication within 48 hours
* any other contraindication of CE-CT
* BMI \> or = 30

Primary outcomes:
measure: Lesion conspicuity
timeFrame: 12 months after CT
Secondary outcomes:
measure: image noise
timeFrame: 12 months after CT
measure: beam hardening artifact
timeFrame: 12 months after CT
measure: hepatic artery conspicuity
timeFrame: 12 months after CT
measure: portal vein conspicuity
timeFrame: 12 months after CT
measure: image texture (plasticity)
timeFrame: 12 months after CT
measure: overall image quality
timeFrame: 12 months after CT
measure: presence of hepatic artery anatomic variation
timeFrame: 12 months after CT
measure: sensitivity to detect HCC
timeFrame: 18 months after CT
measure: radiation dose
timeFrame: 1 month after CT
Other outcomes:
measure: contrast media iodine amount
timeFrame: 1 month after CT
measure: adverse effect
timeFrame: 1 month after CT
measure: Enhancement degree
timeFrame: 12 months after CT
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jeong Min Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yoon JH, Chang W, Lee ES, Lee SM, Lee JM. Double Low-Dose Dual-Energy Liver CT in Patients at High-Risk of HCC: A Prospective, Randomized, Single-Center Study. Invest Radiol. 2020 Jun;55(6):340-348. doi: 10.1097/RLI.0000000000000643.
Clinical trial NCT01988545: GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow
Official title: GLP-1's Influence on Intestinal Blood Flow
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Keywords: GLP-1
blood flow
cardiac out put
stroke volume
beat to beat
effect of GLP-1 on cardiac parameters and blood flow
Lead sponsor: Zealand University Hospital
Sponsor class: OTHER
Collaborators: name: University of Copenhagen
name: Glostrup University Hospital, Copenhagen
First posted: 2013-11-20
Enrollment: 8
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters

Detailed description: to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters, in healthy subjects, 4 arms, task force monitor

Eligibility criteria: Inclusion Criteria:

* healthy subjects

Exclusion Criteria:

* medical conditions

Primary outcomes:
measure: blood flow
timeFrame: with in 120 minutes
Secondary outcomes:
Other outcomes:
measure: cardiac parameters
timeFrame: with in 120 minutes
Locations:
city: Køge
country: Denmark
facility: Køge Hospital
state: State...
Study officials:
affiliation: Køge Hospital
name: Lasse Bremholm, MD, ph.d.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06300645: SPLATT to Peroneus Brevis vs TATT to Lateral Cuneiform
Official title: Split Tibialis Anterior Tendon Transfer to Peroneus Brevis vs Total Tibialis Anterior Tendon Transfer to Lateral Cuneiform in Recurrent Congenital Talipes Equinovarus: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Recurrent Congenital Talipes Equinovarus
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-03-08
Enrollment: 25
Sex: ALL
Minimum age (years): 4
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Congenital talipes equinovarus, is a common congenital foot deformity involving hindfoot equinus and varus, along with mid-/forefoot adduction and cavus. Currently, the Ponseti method is the preferred initial treatment for idiopathic clubfoot1

. Despite the initial phase's remarkable efficacy in correcting clubfeet, there remains a notable recurrence rate after Ponseti treatment2

* Numerous studies demonstrate a very high success rate during early follow-ups, ranging from 92% to 100%3
* Nonetheless, recurrence remains a challenge for orthopedic surgeons. A common trigger for recurrence is the dynamic supination of the foot, which results from excessive activation of the tibialis anterior muscle during ankle dorsiflexion4

Multiple studies indicate that tibialis anterior tendon transfer (TATT) is an effective tool for management of clubfoot recurrence, particularly dynamic supination5

* The widely used technique involves transferring the entire tendon through a drill hole in the lateral cuneiform and anchoring it on the plantar aspect of the foot using a sewing button and felt pad6
* While effective, this procedure raises the risk of pressure sores due to button placement on the sole7

Split anterior tibialis tendon transfer (SPLATT) to peroneus brevis is a well-described treatment strategy of varus foot deformities in patients with neuromuscular disorders8

* The technique has been reported to achieve successful deformity correction while avoiding skin problems associated with external button placement on the sole of the foot in tendon-to-bone transfers8

The present study aims to assess the outcome of utilizing SPLATT to peroneus brevis procedure in the treatment of recurrent CTEV in comparison to the original total TATT to the lateral cuneiform


Eligibility criteria: Inclusion Criteria:

* Recurrent CTEV
* Age between 4 years and 12 years
* Unilateral/bilateral
* Ankle dorsiflexion of at least 10° prior to tendon transfer

Exclusion Criteria:

* Non idiopathic CTEV
* Rigid deformity not suitable for acute correction
* Poor skin condition

Primary outcomes:
measure: Correction of recurrent congenital talipes
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university hospital
Study officials:
References:
Clinical trial NCT04101045: Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes
Official title: Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Type 1 Diabetes
De Novo Lipogenesis
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Juvenile Diabetes Research Foundation
First posted: 2019-09-24
Enrollment: 7
Sex: ALL
Minimum age (years): 13
Maximum age (years): 22
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to quantitate hepatic de novo lipogenesis (DNL) in youth with poorly-controlled type 1 diabetes (T1D) (HbA1c \>8.5%), youth with T1D who achieve targeted glycemic control (HbA1c \<7.5%) and lean controls. Hypothesis: Youth with poor glycemic control experience higher fractional hepatic DNL during the fasting and the postprandial states than youth who achieve targeted glycemic control and lean controls.

Detailed description: What is not known, is whether hepatic de novo lipogenesis (DNL) contributes to dyslipidemia in this in patients with type 1 diabetes (T1D). The aim of the study is to test the hypothesis that an enhanced rate of DNL largely contributes to dyslipidemia occurring in youth with poorly-controlled T1D. According to this hypothesis, youth with poorly-regulated T1D experience a state of persistent insulin independent, highly variable fluctuations of glucose, and other sugars, through the glycolytic pathway that result in an enhancement of hepatic DNL and an increased production of triglycerides (TG). Newly-formed TG are packaged into large-VLDL that are secreted into the circulation contributing to an increase in plasma TG. When the TG concentration in the hepatocytes exceeds the ability of the liver to secrete TG, the latter start accumulating leading to hepatic steatosis.

Eligibility criteria: Inclusion Criteria:

* HbA1c \>8.5% for the group with poorly controlled diabetes
* HbA1c \<7.5% for the well-controlled patients
* T1D for at least 12 months (T1D groups only)
* Negative pregnancy test (all groups)

Exclusion Criteria:

* Baseline creatinine \>1
* Being on medications affecting glucose concentrations other than insulin
* Positive pregnancy test
* Endocrinopathies

Primary outcomes:
measure: Fractional hepatic DNL
timeFrame: Baseline to Six hours
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
Study officials:
affiliation: Assistant Professor of Pediatrics (Endocrinology)
name: Nicola Santoro, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Monga Kravetz A, Testerman T, Galuppo B, Graf J, Pierpont B, Siebel S, Feinn R, Santoro N. Effect of Gut Microbiota and PNPLA3 rs738409 Variant on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Youth. J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3575-85. doi: 10.1210/clinem/dgaa382.
Clinical trial NCT04517045: The Study of Dachengqi Decoction Combined With Probiotic L92 to Improve the Prognosis of Patients With Severe Abdominal Hypertension
Official title: The Study of Dachengqi Decoction Combined With Probiotic L92 to Improve the Prognosis of Patients With Severe Abdominal Hypertension
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Dachengqi Decoction
Probiotic L92
Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2020-08-18
Enrollment: 752
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with severe infections, wounds (burns), and severe pancreatitis often have abdominal hypertension (IAH), which is an important objective manifestation of acute gastrointestinal failure in severe patients. Timely diagnosis and effective intervention can improve the treatment rate of patients. In the early stage, we conducted clinical exploration and observational research on the treatment of IAH with Dachengqi Decoction and Lactobacillus in the treatment of critically ill patients including the above diseases, and achieved significant clinical effects. On this basis, it is planned to verify the protective effect of Lactobacillus acidophilus L92, Dachengqi Decoction and the combination of the two on the gastrointestinal mucosal barrier function of patients with IAH and the regulation of the intestinal flora, and analyze the intestinal mucosal barrier The relationship between intestinal flora and the prognosis of IAH patients.


Eligibility criteria: Inclusion Criteria:

* Inclusion and exclusion criteria and critically ill patients (acute severe pancreatitis, cervical spinal cord injury) who are 60 years old or older than 18 years old, expected to be mechanically ventilated in the ICU, and hospitalized for more than 48 hours, replaced intra-abdominal pressure monitoring with bladder pressure measurement, and repeated on admission The results of the three measurements are ≥12 mmHg.

Exclusion Criteria:

* Patients who have not signed the informed consent; cannot tolerate intra-abdominal pressure monitoring; pregnant women; patients after bladder surgery; systemic diseases and recent use of related drugs; previous infections, such as history of tuberculosis or PPD positive; previous high History of blood pressure, poor blood pressure control (SBP/DBP\>=140mmHg); patients with severe mental illness; long-term use of traditional Chinese medicine, probiotics, gastric mucosal protectors, proton pump inhibitors, chemotherapy or immunosuppressive drugs, etc., such as admission The drug was not discontinued within the previous month.

Primary outcomes:
measure: Incidence of sepsis within 7 days
timeFrame: six months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02860845: Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections
Official title: Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Candidiasis
Vaginosis, Bacterial
Lead sponsor: Laboratorios Ordesa
Sponsor class: INDUSTRY
Collaborators: name: Clever Instruments S.L.
First posted: 2016-08-09
Enrollment: 48
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether a formula of boric acid and probiotics for vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis in comparison to pharmacological reference controls (depending on the suspected diagnosis).

Detailed description: Multicentre, Open, Prospective, Randomized, Controlled. Women with suspected vaginal infection will be randomized and distributed into two groups (control or boric acid + probiotics). Follow-up will last for three months and consists in 3 visits and a telephone interview.

Eligibility criteria: Inclusion Criteria:

* Age over 18 years and agreement to participate by signing the consent form.
* Women with clinical manifestations of acute infectious vulvovaginitis (burning, pruritus, erythema, oedema, and abnormal vaginal discharge).

Exclusion Criteria:

* Clinical findings compatible with Chlamydia trachomatis, Neisseria gonorrhoeae or Trichomonas vaginalis infection.
* Use of anti-fungal, antibiotic or probiotic medication within last 2 weeks prior to the study.
* Patients receiving other treatment (drug, probiotics or vitamin supplements) that can significantly interfere with study evaluations during the 3 months of follow-up.
* Pregnant or high risk for pregnancy.

Primary outcomes:
measure: Change in the Presence of Vaginitis Clinical Symptoms Determined by Sobel Score.
timeFrame: Baseline and at 2 weeks after treatment finalization
Secondary outcomes:
measure: Change in the Level of Lactobacillus in Vaginal Flora Determined by Vaginal Cultures.
timeFrame: Baseline and 2 weeks after treatment finalization
measure: Number of Participants With Recurrent Infections
timeFrame: At 3 months after recruitment
Other outcomes:
Locations:
city: Sevilla
country: Spain
facility: Ginemed Sevilla
state: Andalucía
Study officials:
affiliation: Ginemed Sevilla
name: Juan A Tena, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01533545: Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
Official title: Effect of Epinephrine on Systemic Absorption of Mepivacaine Administered for Brachial Plexus Block in Patients With Chronic Renal Insufficiency
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Renal Insufficiency, Chronic
Keywords: Mepivacaine
Epinephrine
Brachial plexus block
Renal insufficiency
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2012-02-15
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine the effect of epinephrine on systemic absorption of local anaesthetic mepivacaine administered for brachial plexus block in uremic patients scheduled for creation or repair of an arteriovenous fistula. Furthermore, an impact of epinephrine on the central circulation and peripheral tissue oxygenation will be evaluated.


Eligibility criteria: Inclusion Criteria:

* patient acceptance of regional anaesthesia

Exclusion Criteria:

* peripheral arteriosclerosis
* diabetes mellitus
* bleeding disorder
* infection at the puncture site
* allergy to mepivacaine
* pregnancy

Primary outcomes:
measure: Plasma concentration of mepivacaine
timeFrame: 0, 5, 10, 20, 30, 45, 60, 120, and 180 min after blockade
Secondary outcomes:
measure: Central circulation
timeFrame: 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 min after blockade
measure: Peripheral tissue oxygenation
timeFrame: 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 min after blockade
measure: Cardiotoxicity of local anesthetic
timeFrame: 0, 5, 10, 20, 30, 45, and 60 min after blockade
measure: Neurotoxicity of local anesthetic
timeFrame: Continuously for 1 hour after blockade
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
Study officials:
affiliation: Rigshospitalet, Denmark
name: Robertas Martusevicius, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: McEllistrem RF, Schell J, O'Malley K, O'Toole D, Cunningham AJ. Interscalene brachial plexus blockade with lidocaine in chronic renal failure--a pharmacokinetic study. Can J Anaesth. 1989 Jan;36(1):59-63. doi: 10.1007/BF03010889.
citation: Norio K, Makisalo H, Isoniemi H, Groop PH, Pere P, Lindgren L. Are diabetic patients in danger at renal transplantation? An invasive perioperative study. Eur J Anaesthesiol. 2000 Dec;17(12):729-36. doi: 10.1046/j.1365-2346.2000.00760.x.
citation: Niemi G. Advantages and disadvantages of adrenaline in regional anaesthesia. Best Pract Res Clin Anaesthesiol. 2005 Jun;19(2):229-45. doi: 10.1016/j.bpa.2004.12.004.
citation: Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med. 2004 Nov-Dec;29(6):564-75; discussion 524. doi: 10.1016/j.rapm.2004.08.003.
Clinical trial NCT03612245: Hygiene and Bucco-dental Status of Patients With Oral Streptococcal Endocarditis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infective Endocarditis
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
Collaborators: name: Bichat Hospital
name: Central Hospital, Nancy, France
name: CHU de Reims
name: Pitié-Salpêtrière Hospital
name: Rennes University Hospital
First posted: 2018-08-02
Enrollment: 403
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with definite IE treated in one of the participating hospitals.

Brief summary: Infective endocarditis (IE) is a rare (30 cases / million / year in France) and serious disease (20 % of deaths during hospitalization and 40 % after 5 years). The development of an IE results from the meeting between a bacteremia and a pre-existent heart disorder, most of the time valvular, allowing the transplant of the circulating bacteria and their multiplication in the endocardium. Recommendations of prophylactic antibiotic treatment have been established since 1954 for some medical, particularly dental procedures, at the origin of bacteremia. But this policy has recently been questioned because its efficacy has not been demonstrated.

The purpose of this study is identify the situations with risk, by comparing the oral health status and the hygiene of patients having an IE with oral streptococci to those in patients having an IE with microorganisms not of oral origin.

Detailed description: It is a case-control observational study. The IE cases are recruited in hospitals participating to the french prospective observational "EI2008" cohort.

Cases are IE with oral streptococci whereas controls are IE with microorganisms not of oral origin.

Eligibility criteria: Inclusion Criteria:

* Major patient
* Definite IE caused by oral streptococci (case) or by non-oral pathogens (control)

Exclusion Criteria:

-

Primary outcomes:
measure: Oral health status
timeFrame: During the IE event
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Duval X, Millot S, Chirouze C, Selton-Suty C, Moby V, Tattevin P, Strady C, Euvrard E, Agrinier N, Thomas D, Hoen B, Alla F; EI-dents Association pour l'Etude et la Prevention de l'Endocardite Infectieuse (AEPEI) Study Group. Oral Streptococcal Endocarditis, Oral Hygiene Habits, and Recent Dental Procedures: A Case-Control Study. Clin Infect Dis. 2017 Jun 15;64(12):1678-1685. doi: 10.1093/cid/cix237.